| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.05 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | 0.045 | 0.8 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |